Planning a pregnancy when you have inflammatory bowel disease (IBD) raises important questions about disease control, medication safety, and the health of both you and your baby. Most women with IBD can have healthy pregnancies, but timing and preparation matter. Understanding how inflammation affects fertility and pregnancy outcomes helps you make informed decisions with your healthcare team.
Why disease activity matters
The single most important factor for a successful pregnancy in IBD is achieving and maintaining remission before you conceive. Active inflammation at conception or during pregnancy increases the risk of complications including miscarriage, preterm birth, low birth weight, and flare during pregnancy.
Women with quiescent disease have pregnancy outcomes similar to the general population. In contrast, active disease at conception is associated with poorer outcomes for both mother and baby. Ongoing intestinal inflammation can affect nutrient absorption, increase inflammatory signalling throughout the body, and place additional stress on the immune system.
The goal is to plan conception during stable remission, ideally for at least three to six months beforehand. This allows time for your body to recover from previous inflammation, for nutrient stores to be replenished, and for you and your medical team to optimise your treatment plan.
Medication safety and planning
Many women worry about taking IBD medications during pregnancy, but the evidence is clear: the risk of uncontrolled inflammation to both mother and baby is far greater than the risk posed by most IBD medications. Stopping treatment to conceive often leads to flare, which can be harder to control during pregnancy and carries significant risk.
Most IBD medications used to maintain remission are considered low risk during pregnancy. These include most aminosalicylates such as mesalazine, many immunomodulators including azathioprine and mercaptopurine, and most biologic therapies including anti-TNF agents such as infliximab and adalimumab. These medications have been used by thousands of pregnant women with IBD, and the data supports their continued use.
A small number of medications do require adjustment. Methotrexate must be stopped at least three months before conception because it can cause serious birth defects. Some newer small molecule therapies may require individual discussion with your gastroenterologist. Your doctor will review your current regimen and may adjust doses or timing, but the principle remains: maintaining remission is the priority.
Do not stop or reduce your medication without discussing it with your IBD team. If you have concerns about a specific drug, raise them early so alternatives can be considered whilst you are still in remission.
Nutritional status and supplementation
Active IBD, even in the past, can deplete key nutrients critical for healthy pregnancy. Inflammation in the gut reduces absorption of iron, folate, vitamin B12, vitamin D, calcium, and zinc. Many of these nutrients play essential roles in fetal development and maternal health.
Folate is particularly important for normal neural tube development in the first weeks of pregnancy, often before a woman knows she is pregnant. All women planning pregnancy are advised to take 400 micrograms of folic acid daily, but women with IBD, especially those taking sulfasalazine, which can interfere with folate metabolism, may need a higher dose. Speak with your doctor about the right dose for you.
Iron deficiency is common in IBD due to chronic blood loss and inflammation. Anaemia during pregnancy increases the risk of preterm birth and low birth weight. If your iron stores are low, they should be corrected before conception. Vitamin D status should also be checked, as deficiency is linked to poorer pregnancy outcomes and may influence immune regulation.
A balanced, nutrient-dense diet is the foundation, but supplementation is often needed. Work with a dietitian experienced in IBD to assess your nutritional status before you conceive.
Fertility and conception
IBD itself does not usually reduce fertility in women, provided the disease is in remission. However, active inflammation, previous surgery, and certain complications can affect your ability to conceive. Women with a history of pelvic or abdominal surgery, particularly those with a pouch or scarring near the fallopian tubes, may experience reduced fertility.
If you have been trying to conceive for six months without success, or if you have had previous surgery that might affect fertility, discuss this with your gastroenterologist and consider referral to a fertility specialist.
Men with IBD should also be aware that sulfasalazine can temporarily reduce sperm count and motility. Switching to an alternative aminosalicylate such as mesalazine usually reverses this effect within a few months.
Planning with your healthcare team
Preconception planning is a collaborative process. Ideally, meet with your gastroenterologist at least three to six months before you plan to conceive. This appointment allows time to review disease activity, confirm remission, optimise medication, check nutritional status, and discuss any concerns.
Your gastroenterologist may arrange blood tests to check inflammatory markers, haemoglobin, ferritin, vitamin D, and vitamin B12. If you are on a biologic therapy, the timing of doses around conception and during pregnancy may be discussed, although most can be continued safely.
Inform your general practitioner and arrange early referral to obstetrics once pregnant. Pregnancy in IBD is considered higher risk and benefits from shared care between gastroenterology and obstetrics. In some centres, specialist joint clinics exist for this purpose.
Practical takeaways
- Aim to conceive during stable remission, ideally after three to six months of quiescent disease.
- Continue your IBD medications unless specifically advised otherwise by your gastroenterologist.
- Start folic acid supplementation at least three months before trying to conceive, and discuss the correct dose with your doctor.
- Have your nutritional status checked, including iron, vitamin D, folate, and vitamin B12, and address any deficiencies before conception.
- Meet with your gastroenterology team to review your treatment plan and confirm remission before you start trying.
- Involve your partner in discussions, especially if male fertility may be affected by medication.
Conclusion
Pregnancy with IBD is not only possible but often successful when planned carefully. The most important step is achieving and maintaining remission before you conceive. Most IBD medications are safe to continue, and stopping treatment can lead to flare, which poses greater risk than the medication itself. Early planning, nutritional optimisation, and close collaboration with your healthcare team give you the best chance of a healthy pregnancy and a healthy baby.
References
- Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(5):460-466. doi:10.1111/apt.12417
- Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019;156(5):1508-1524. doi:10.1053/j.gastro.2018.12.022
- de Lima A, Zelinkova Z, Mulders AG, van der Woude CJ. Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol. 2016;14(9):1285-1292. doi:10.1016/j.cgh.2016.03.018
- Narula N, Al-Dabbagh R, Dhillon A, et al. Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(10):1862-1869. doi:10.1097/MIB.0000000000000092
- van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9(2):107-124. doi:10.1093/ecco-jcc/jju006
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.